July 30, 2026 · Form 4 insider transaction
Mokari Atabak sold 8,267 shares of Corcept Therapeutics Incorporated at $117.93 per share, a transaction worth $975.0K. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 4 days after the transaction.
This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.; Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.41 to $118.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.; Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.